Showing results (191-200 of 399) with videos related to
Sort By:
Pageof 40
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2022
STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma modelsGilles Berger, Erik H Knelson, Jorge L Jimenez-Macias, et al.Oncotarget|January 19, 2017
MicroRNA-140 mediates RB tumor suppressor function to control stem cell-like activity through interleukin-6Akiyo Yoshida, Shunsuke Kitajima, Fengkai Li, et al.Scientific Reports|August 20, 2016
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironmentPatrick H Lizotte, Robert E Jones, Lauren Keogh, et al.Blood|August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.Blood Advances|May 31, 2022
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosisAndreas Reiter, Juliana Schwaab, Daniel J DeAngelo, et al.The Journal of Clinical Investigation|September 12, 2017
Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinasesHiroshi Nishi, Kazuhiro Furuhashi, Xavier Cullere, et al.Investigational New Drugs|April 27, 2011
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemiaSimona Lapusan, Maria B Vidriales, Xavier Thomas, et al.Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.Plos Medicine|July 13, 2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman, Benjamin H Lee, Thomas Mercher, et al.Pageof 40